Abstract
COVID-19 has become a great national security problem for the United States and many other countries, where public policy and healthcare decisions are based on the several models for the prediction of the future deaths and cases of COVID-19. While the most commonly used models for COVID-19 include epidemiological models and Gaussian curve-fitting models, recent literature has indicated that these models could be improved by incorporating machine learning. However, within this research on potential machine learning models for COVID-19 forecasting, there has been a large emphasis on providing an array of different types of machine learning models rather than optimizing a single one. In this research, we suggest and optimize a linear machine learning model with a gradient-based optimizer for the prediction of future COVID-19 cases and deaths in the United States. We also suggest that a hybrid of a machine learning model for shorter range predictions and a Gaussian curve-fitting model or an epidemiological model for longer range predictions could greatly increase the accuracy of COVID-19 forecasting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author received no financial support for the research and authroship for this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The author has not obtained IRB approval for the research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available in the covid-19-data repository in the New York Times' Github.